Heart failure with preserved ejection fraction: JACC scientific statement
The incidence and prevalence of heart failure with preserved ejection fraction (HFpEF)
continue to rise in tandem with the increasing age and burdens of obesity, sedentariness …
continue to rise in tandem with the increasing age and burdens of obesity, sedentariness …
The role of machine learning in clinical research: transforming the future of evidence generation
Background Interest in the application of machine learning (ML) to the design, conduct, and
analysis of clinical trials has grown, but the evidence base for such applications has not …
analysis of clinical trials has grown, but the evidence base for such applications has not …
[HTML][HTML] Anticoagulation with edoxaban in patients with atrial high-rate episodes
P Kirchhof, T Toennis, A Goette, AJ Camm… - … England Journal of …, 2023 - Mass Medical Soc
Background Device-detected atrial high-rate episodes (AHREs) are atrial arrhythmias
detected by implanted cardiac devices. AHREs resemble atrial fibrillation but are rare and …
detected by implanted cardiac devices. AHREs resemble atrial fibrillation but are rare and …
[HTML][HTML] Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction
Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of
hospitalization for heart failure and cardiovascular death among patients with chronic heart …
hospitalization for heart failure and cardiovascular death among patients with chronic heart …
Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research
VARC-3 Writing Committee, P Généreux… - European heart …, 2021 - academic.oup.com
Abstract Aims The Valve Academic Research Consortium (VARC), founded in 2010, was
intended to (i) identify appropriate clinical endpoints and (ii) standardize definitions of these …
intended to (i) identify appropriate clinical endpoints and (ii) standardize definitions of these …
[HTML][HTML] Glycemia reduction in type 2 diabetes—microvascular and cardiovascular outcomes
GRADE Study Research Group - New England Journal of …, 2022 - Mass Medical Soc
Background Data are lacking on the comparative effectiveness of commonly used glucose-
lowering medications, when added to metformin, with respect to microvascular and …
lowering medications, when added to metformin, with respect to microvascular and …
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
Aims Sodium–glucose co‐transporter 2 (SGLT2) inhibitors, originally developed as glucose‐
lowering agents, have been shown to reduce heart failure hospitalizations in patients with …
lowering agents, have been shown to reduce heart failure hospitalizations in patients with …
Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial
Background: Empagliflozin reduces the risk of cardiovascular death or hospitalization for
heart failure in patients with heart failure and a reduced ejection fraction, with or without …
heart failure in patients with heart failure and a reduced ejection fraction, with or without …
Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque
Background: Immune checkpoint inhibitors (ICIs) treat an expanding range of cancers.
Consistent basic data suggest that these same checkpoints are critical negative regulators of …
Consistent basic data suggest that these same checkpoints are critical negative regulators of …
Med-BERT: pretrained contextualized embeddings on large-scale structured electronic health records for disease prediction
Deep learning (DL)-based predictive models from electronic health records (EHRs) deliver
impressive performance in many clinical tasks. Large training cohorts, however, are often …
impressive performance in many clinical tasks. Large training cohorts, however, are often …